Search clinical trials for: veltuzumab

Total 482 results

Gilead Sciences

Completed

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Lymphoma, Diffuse | Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic

France, United Kingdom
Gilead Sciences

Terminated

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Purpura, Thrombocytopenic, Idiopathic | Autoimmune Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Autoimmune

United States
Gilead Sciences

Completed

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic | Leukemia, Prolymphocytic | NHL | CLL | Leukemia, Lymphocytic, Chronic | Lymphoma, Intermediate-Grade | Lymphoma, Large-Cell | Lymphoma, Mixed-Cell | Lymphoma, Small-Cell | Leukemia, B-Cell, Chronic | Leukemia... and other conditions

United States
Shanghai Henlius Biotech

Completed

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
Boehringer Ingelheim

Completed

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Queen Mary University of London
Gilead Sciences

Unknown

Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

United Kingdom
Zydus Lifesciences Limited

Not yet recruiting

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Metastatic Breast Cancer
Nantes University Hospital
Chugai Pharmaceutical; French Innovative Leukemia Organisation

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)

Acute Myeloid Leukemia

France
Abbott
Bristol-Myers Squibb

Terminated

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Multiple Myeloma

United States
Shengjing Hospital

Not yet recruiting

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Breast Cancer

China
Gilead Sciences

Completed

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche

Completed

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Elderly Metastatic Breast Cancer Population

Belgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
PETHEMA Foundation

Completed

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Acute Myeloblastic Leukemia

Spain
University Hospital Carl Gustav Carus

Unknown

Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Allogeneic Transplantation

Germany
Pfizer

Completed

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Leukemia, Myeloid, Acute

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Ovarian Cancer
Pfizer

Completed

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
Beth Christian
Gilead Sciences

Completed

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
University of Aarhus

Completed

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Denmark
Pfizer

Completed

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
University Hospital Heidelberg

Terminated

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)

Acute Myeloid Leukemia

Germany
Bristol-Myers Squibb
AbbVie

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
Genentech, Inc.

Completed

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

Prostate Cancer
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19)

Leukemia

Belgium, Italy, Netherlands
Versailles Hospital

Unknown

Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg® (MYLOR)

Leukemia, Myeloid, Acute

France
Biocad

Recruiting

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (PREFER)

Breast Cancer

Russian Federation
Ontario Clinical Oncology Group (OCOG)

Terminated

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (PETRA)

Breast Cancer

Canada
Pfizer

Completed

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Pharmacokinetics | Safety | ECG

Canada, Spain, United States, Hungary, Poland, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Acute Myelogenous Leukemia

United States
Kanisa Pharmaceuticals

Completed

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Leukemia, Myeloid
Biocad

Active, not recruiting

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Breast Cancer

Russian Federation
Merck Sharp & Dohme LLC

Terminated

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Leukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Breast Cancer

United States
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
Memorial Sloan Kettering Cancer Center

Completed

Imaging With a New Agent That Finds a Cancer Protein Called HER2

HER2-positive Carcinoma | HER2-positive Primary Malignancy

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Roche Pharma AG

Completed

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (TRAP)

Esophageal Carcinoma

Netherlands
Gilead Sciences

Withdrawn

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Diffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHL

United States
Acute Leukemia French Association

Completed

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (MYLOFRANCE2)

Acute Myeloid Leukemia

France
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Genta Incorporated

Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Weill Medical College of Cornell University
Gilead Sciences

Terminated

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Follicular Lymphoma

United States
Hospices Civils de Lyon

Not yet recruiting

PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study (PETRA)

HER-2 Positive Breast Cancer

France
University Hospital Heidelberg
National Center for Tumor Diseases, Heidelberg

Completed

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM)

Acute Myeloid Leukemia

Germany
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Weill Medical College of Cornell University
Pfizer; Jazz Pharmaceuticals

Terminated

CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO)

Acute Myeloid Leukemia

United States

3

Subscribe